« The Latest Protein-Protein Compounds |
| Changing A Broken Science System »
April 16, 2014
One and Done
Matthew Herper has a good piece in Forbes on Robert Duggan and Pharmacyclics. In the course of it, we learn this interesting (and perhaps disturbing) bit of information:
Second acts in the biotech business are hard: 56% of the drug firms that received an FDA approval between 1950 and 2011 did so only once.
And I hate to say it, but the article does not inspire confidence in Duggan's ability to break that trend. It's surely no coincidence that the profile mentions in its first paragraph that he's a major donor to the Church of Scientology, and maybe it's just my own prejudices, but when I hear that, I'm pretty much done with thinking that a person can make rational decisions.
+ TrackBacks (0) | Category: Drug Industry History
POST A COMMENT
- RELATED ENTRIES
- Go Home, Gaijin
- The Virtual Clinical Trial: Not Quite Around the Corner
- Stephanie Kwolek, 1923-2014
- Scripps Update
- What If Drug Patents Were Written Like Software Patents?
- Stem Cells: The Center of "Right to Try"
- Speaking of Polyphenols. . .